Cargando…
Prolonged continuous infusion of low-dose rIL-2.
Autores principales: | Janssen, R. A., Buter, J., The, T. H., Mulder, N. H., de Leij, L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968897/ https://www.ncbi.nlm.nih.gov/pubmed/8180034 |
Ejemplares similares
-
Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
por: Janssen, R. A., et al.
Publicado: (1992) -
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
por: Martens, A., et al.
Publicado: (1993) -
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
por: Geertsen, P F, et al.
Publicado: (2004) -
Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)
por: Punt, C. J., et al.
Publicado: (1990) -
Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8(+) T Cells
por: Mooslechner, Agnes A., et al.
Publicado: (2022)